Brentuximab shrunk tumors in resistant Hodgkin lymphoma

Share this content:

An investigational agent for the treatment of Hodgkin lymphoma has yielded very strong results in a phase II trial of heavily pretreated persons with relapsed or refractory disease. Brentuximab vedotin shrunk tumors in 95% of 102 persons participating in the single-arm, multicenter study designed to evaluate the safety and efficacy of this antibody-drug conjugate.

More than 70% of the study participants, who ranged in age from 15 to 77 years (median: 31 years), had primary refractory disease. In the abstract prepared by investigator Robert Chen and colleagues for the annual meeting of the American Society of Hematology, held December 4-7, 2010 (, the researchers defined primary refractory disease as failure to achieve complete remission or experiencing progression within 3 months of completing frontline therapy. All study subjects had previously undergone an autologous stem cell transplant (ASCT) and anywhere from 1 to 13 prior regimens of chemotherapy (median: four regimens). More than a third (39%) had lymphoma that was refractory to the most recent salvage therapy excluding ASCT.

In the current intervention, patients received up to 16 cycles (median: nine cycles) of brentuximab vedotin 1.8 mg/kg every 3 weeks as a 30-minute outpatient IV infusion. The treatment was associated with manageable adverse effects, most commonly peripheral sensory neuropathy, fatigue, nausea, neutropenia, diarrhea, and pyrexia.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs